Based on tehnology developed at Case Western Reserve University (CWRU), Affinity Therapeutics, LLC (AT) is working on the controlled release of therapeutics using molecular interactions to obtain release rates and durations not available by diffusion alone. Utilizing this platform technology, Affinity is poised to change how therapeutics are delivered in several markets, including the advanced wound care and hernia mesh. The company's technology allows for customized controlled-release that is calibrated to a patient's unique needs.
